Author

Zili Fu

Observed names: Hongwei Du, Zi-Li Fu

Institutions: Shanxi Medical University, First Hospital of Shanxi Medical University

Observed institutions: Shanxi Medical University, Sichuan Agricultural University, Central China Normal University, Zaozhuang Municipal Hospital, First Hospital of Shanxi Medical University, Second Hospital of Tianjin Medical University, Second Hospital of Shanxi Medical University, Jinhua Central Hospital, Tianjin Medical University

ORCID: 0000-0003-4888-9876

Observed ORCID: 0000-0003-4888-9876

OpenAlex ID: A5047926686

Effect of Obesity on P‐Wave Parameters in a Chinese Population

2010 · Tong Liu, Zili Fu, et al. · Annals of Noninvasive Electrocardiology · 19

Decreased Absolute Number of Circulating Regulatory T Cells in Patients With Takayasu’s Arteritis

2021 · Wen Jia, Zi-Li Fu, et al. · Frontiers in Immunology · 15

Increased expression of the p-STAT3/IL-17 signaling pathway in patients with dermatomyositis

2022 · Dongmei Li, Wen Jia, et al. · Modern Rheumatology · 7

Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus: a randomized, double-blind, placebo-controlled phase Ib/IIa trial

2025 · Jiuliang Zhao, Changsong Lin, et al. · Signal Transduction and Targeted Therapy · 6

Comparison of the efficacy and safety of methotrexate injection and methotrexate tablets in active RA

2025 · Lin Qiao, Jiankang Hu, et al. · Lara D. Veeken · 6

A Network for Detecting Facial Features During the COVID-19 Epidemic

2021 · Bin Lin, Yanlin Mu, et al. · International Conference on Control Engineering and Artificial Intelligence (CCEAI) · 4

Clinical study on therapeutic effect of three cycle natural therapy on chronic hepatitis B and C

1998 · Ai-Guo Qiu, Rui-Bo Qiu, et al. · World Journal of Gastroenterology · 3

Large language model augmented multi-task learning network with inter-clause modeling for emotion-cause pair extraction

2025 · Zhi Liu, Chaodong Wen, et al. · Information Fusion · 2

Orelabrutinib, an irreversible inhibitor of Bruton’s tyrosine kinase, for the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, phase Ib/IIa study

2025 · Xue Li, Ru Li, et al. · Research Square · 1

Orelabrutinib for systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study

2026 · Ru Li, Xue Li, et al. · Journal of Autoimmunity

Efficacy and safety of Janus kinase 1/2 inhibitor KL130008 in active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase II trial

2025 · Yue Cheng, Honghu Tang, et al. · BMC Medicine

Increased Expression of p-STAT3/IL-17 in Muscle Tissues of Patients with dermatomyositis and anti-synthetase syndrome Is Correlated with Disease Activity

2022 · Dongmei Li, Kaixin Qin, et al. · Research Square

Efficacy of tacrolimus combined with methotrezate in the treatment of patients with refractory rheumatoid arthritis

2017 · Dongping Luo, Xiumei Liu, et al.

T-Helper Cell Cytokine Expression Profiling in Rheumatoid Arthritis Patients by Flow Cytometric Bead Array Analysis

2015 · Chen J, Yang J, et al. · International Journal of Clinical Therapeutics and Diagnosis

Works count: 15

Citation count: 63

H-index: 5

I10-index: 2